Recombinant Human Erythroferrone(ERFE), partial

Catalog No: #AP89512



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Description	Support: tech@signalwayantibody.com
Product Name	Recombinant Human Erythroferrone(ERFE),partial
Brief Description	Recombinant Protein
Host Species	Yeast
Purification	Greater than 90% as determined by SDS-PAGE.
Species Reactivity	Homo sapiens (Human)
Target Name	ERFE
Other Names	Complement C1q tumor necrosis factor-related protein 15 (Myonectin) (C1QTNF15) (CTRP15) (FAM132B)
Accession No.	Uniprot ID: Q4G0M1
Calculated MW	19.5 kDa
Tag Info	N-terminal 6xHis-tagged
Target Sequence	PGPRAPRVEAAFLCRLRRDALVERRALHELGVYYLPDAEGAFRRGPGLNLTSGQYRAPVAGFYALAATLHVA
	${\sf LGEPPRRGPPRPRDHLRLLICIQSRCQRNASLEAIMGLESSSELFTISVNGVLYLQMGQWTSVFLDNASGCSL}$
	TVRSGSHFSAVLLGV
Storage	The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability
	of the protein itself. Generally, the shelf life of liquid form is 6 months at $-200\Omega\frac{1}{2}$? - $800\Omega\frac{1}{2}$? The shelf life of
	lyophilized form is 12 months at $-200\Omega\frac{1}{2}$? $-800\Omega\frac{1}{2}$?

Application Details

Expression Region: 195-354aa

Relevance: Iron-regulatory hormone that acts as an erythroid regulator after hemorrhage: produced by erythroblasts following blood loss and mediates suppression of hepcidin expression in the liver, thereby promoting increased iron absorption and mobilization from stores. Promotes lipid uptake into adipocytes and hepatocytes via transcriptional up-regulation of genes involved in fatty acid uptake.

Storage Buffer: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.

Notes: Repeated freezing and thawing is not recommended. Store working aliquots at $40\Omega\frac{1}{2}$?for up to one week.

References

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis. Honda H., Kobayashi Y., Onuma S., Shibagaki K., Yuza T., Hirao K., Yamamoto T., Tomosugi N., Shibata T. PLoS ONE 11:e0151601-e0151601(2016)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.